Is ONCSQ or DVY a better dividend investment in 2026?

ONCSQ currently yields 2000000.00% with a 5% 5-year dividend growth rate. DVY yields 3.46% with 5% growth. The better choice depends on your goal: ONCSQ offers higher current income.

What is the dividend yield difference between ONCSQ and DVY?

ONCSQ has a forward dividend yield of 2000000.00% ($2.00/share annually). DVY yields 3.46% ($5.25/share annually). The yield gap is 1999996.54 percentage points.

Home › Compare › ONCSQ vs DVY

ONCSQ vs DVY: Dividend Comparison 2026

ONCSQ yields 2000000.00% · DVY yields 3.46%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ONCSQ wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ONCSQ

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full ONCSQ calculator →

DVY

● Live price

3.46%

Share price

$151.41

Annual div

$5.25

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.0K

Annual income

$432.91

Full DVY calculator →

Portfolio growth — ONCSQ vs DVY

📍 ONCSQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ONCSQ	DVY
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ONCSQ + DVY cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ONCSQ pays

DVY pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ONCSQ

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

DVY

Annual income on $10K today (after 15% tax)

$294.47/yr

After 10yr DRIP, annual income (after tax)

$367.97/yr

At 15% tax rate, ONCSQ beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ONCSQ + DVY for your $10,000?

ONCSQ: 50%DVY: 50%

100% DVY50/50100% ONCSQ

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is split right now

ONCSQ

Analyst Ratings

Hold

Consensus: Hold

Altman Z

-59.7

Piotroski

2/9

DVY

No analyst data

Altman Z

307.5

Piotroski

1/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ONCSQ buys

DVY buys

No recent congressional trades found for ONCSQ or DVY in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricONCSQDVY

Forward yield	2000000.00% ✓	3.46%
Annual dividend / share	$2.00	$5.25 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4.879226400974806e+39M	$25.0K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$432.91
Total dividends collected	$4.879195005460081e+39M ✓	$3.9K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ONCSQ vs DVY ($10,000, DRIP)

Year	ONCSQ Portfolio	ONCSQ Income/yr	DVY Portfolio	DVY Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$11,046	$346.43	+$200.00M → ONCSQ
2	$3,738,731,768,458	$3,738,517,757,009.35	$12,177	$357.65	+$3738731.76M → ONCSQ
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$13,398	$368.47	+$65315062866.92M → ONCSQ
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$14,715	$378.89	+$1066400830062625.00M → ONCSQ
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$16,134	$388.90	+$16272182796453826560.00M → ONCSQ
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$17,662	$398.51	+$2.3205424011366188e+23M → ONCSQ
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$19,306	$407.71	+$3.0927990661046884e+27M → ONCSQ
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$21,074	$416.50	+$3.8524105697352695e+31M → ONCSQ
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$22,974	$424.90	+$4.484688260147987e+35M → ONCSQ
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$25,015	$432.91	+$4.879226400974806e+39M → ONCSQ

ONCSQ vs DVY: Complete Analysis 2026

ONCSQ — Stock

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. On June 14, 2023, OncoSec Medical Incorporated filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey.

Full ONCSQ Calculator →

DVY — ETF

The iShares Select Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full DVY Calculator →

📬

Get this ONCSQ vs DVY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ONCSQ vs SCHD ONCSQ vs JEPI ONCSQ vs O ONCSQ vs KO ONCSQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.